MarketBeat | Real-Time Financial News and Analysis

Open Main Menu Open Sidebar

BioMarin Pharmaceutical Company Profile (NASDAQ:BMRN)

Consensus Ratings for BioMarin Pharmaceutical (NASDAQ:BMRN) (?)
Ratings Breakdown: 2 Hold Rating(s), 18 Buy Rating(s), 1 Strong Buy Rating(s)
Consensus Rating:Buy (Score: 2.95)
Consensus Price Target: $128.67 (46.30% upside)

Analysts' Ratings History for BioMarin Pharmaceutical (NASDAQ:BMRN)
Show:
DateFirmActionRatingPrice TargetActions
4/30/2016Cowen and CompanyReiterated RatingBuyView Rating Details  Tweet This Rating  Share This Rating on StockTwits
4/29/2016Credit SuisseReiterated RatingBuy$114.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
4/26/2016OppenheimerReiterated RatingHold$99.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
4/20/2016Piper JaffrayReiterated RatingBuyView Rating Details  Tweet This Rating  Share This Rating on StockTwits
4/19/2016WedbushReiterated RatingNeutral$108.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
4/8/2016Jefferies GroupReiterated RatingBuy$120.00 -> $116.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
4/7/2016BMO Capital MarketsInitiated CoverageOutperform$99.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
3/22/2016William BlairReiterated RatingBuyView Rating Details  Tweet This Rating  Share This Rating on StockTwits
3/19/2016Leerink SwannReiterated RatingBuyView Rating Details  Tweet This Rating  Share This Rating on StockTwits
3/8/2016Robert W. BairdInitiated CoverageBuyView Rating Details  Tweet This Rating  Share This Rating on StockTwits
3/8/2016JPMorgan Chase & Co.Reiterated RatingBuyView Rating Details  Tweet This Rating  Share This Rating on StockTwits
3/7/2016Goldman SachsUpgradeBuy -> Conviction-Buy$129.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
3/5/2016RBC CapitalReiterated RatingBuyView Rating Details  Tweet This Rating  Share This Rating on StockTwits
3/3/2016Stifel NicolausBoost Price TargetBuy$105.00 -> $107.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
2/26/2016BarclaysLower Price TargetOverweight$125.00 -> $105.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
1/15/2016Bank of AmericaReiterated RatingBuy$165.00 -> $135.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
10/13/2015Raymond JamesReiterated RatingOutperform$157.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
8/6/2015Deutsche BankReiterated RatingBuy$160.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
8/4/2015NomuraReiterated RatingBuy$163.00 -> $173.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
8/4/2015SunTrustReiterated RatingBuyView Rating Details  Tweet This Rating  Share This Rating on StockTwits
6/18/2015Canaccord GenuityBoost Price TargetBuy$115.00 -> $150.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
2/26/2015Brean CapitalReiterated RatingHoldView Rating Details  Tweet This Rating  Share This Rating on StockTwits
2/26/2015Citigroup Inc.Reiterated RatingBuy$94.00 -> $133.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
1/29/2015Evercore ISIInitiated CoverageBuyView Rating Details  Tweet This Rating  Share This Rating on StockTwits
11/3/2014Wells FargoUpgradeMarket Perform -> OutperformView Rating Details  Tweet This Rating  Share This Rating on StockTwits
(Data available from 5/24/2014 forward)
            As Featured by CNBC As Featured by The Wall Street Journal As Featured by MarketWatch As Featured by The Boston Globe As Featured by StockTwits As Featured by Seeking Alpha